GMP Peptide Manufacturing at CordenPharma Colorado (US)
In order to accommodate the continuous growth and evolution of the peptide therapeutic market, With approximately 350 employees, CordenPharma Colorado has grown a strong focus in the development & manufacturing of APIs from laboratory-scale to commercialization at ton-scale, due to their unique large-scale SPPS capabilities. The purification of the final peptide is performed at any scale using column chromatography, with columns ranging from 5 cm to 100 cm. To avoid the tedious and poor productivity of the final isolation step by lyophilization, their development team has gained an unmatched expertise in the isolation of peptides by precipitation that has been successfully transferred to production in a number of commercial products. The site has a long record of accomplishment in the large-scale manufacturing of Peptides, where all potencies, including picogram levels, are managed.
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under four Technology Platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma experts translate complex processes and projects at any stage of development into high-value products.
For more information about CordenPharma, CordenPharma Media Contacts
North America
Abby Thompson
abby.thompson@cordenpharma.com
Europe & Asia
Eva Schaub
eva.schaub@cordenpharma.com
